Top

Published in:

Open Access 01-03-2021 | Non-Thematic Review

Secreted frizzled-related protein 2: a key player in noncanonical Wnt signaling and tumor angiogenesis

Authors: Karlijn van Loon, Elisabeth J. M. Huijbers, Arjan W. Griffioen

Published in: Cancer and Metastasis Reviews | Issue 1/2021

Abstract

Secreted frizzled-related proteins (SFRP) are glycoproteins containing a so-called frizzled-like cysteine-rich domain. This domain enables them to bind to Wnt ligands or frizzled (FzD) receptors, making potent regulators of Wnt signaling. As Wnt signaling is often altered in cancer, it is not surprising that Wnt regulators such as SFRP proteins are often differentially expressed in the tumor microenvironment, both in a metastatic and non-metastatic setting. Indeed, SFRP2 is shown to be specifically upregulated in the tumor vasculature of several types of cancer. Several studies investigated the functional role of SFRP2 in the tumor vasculature, showing that SFRP2 binds to FzD receptors on the surface of tumor endothelial cells. This activates downstream Wnt signaling and which is, thereby, stimulating angiogenesis. Interestingly, not the well-known canonical Wnt signaling pathway, but the noncanonical Wnt/Ca²⁺ pathway seems to be a key player in this event. In tumor models, the pro-angiogenic effect of SFRP2 could be counteracted by antibodies targeting SFRP2, without the occurrence of toxicity. Since tumor angiogenesis is an important process in tumorigenesis and metastasis formation, specific tumor endothelial markers such as SFRP2 show great promise as targets for anti-cancer therapies. This review discusses the role of SFRP2 in noncanonical Wnt signaling and tumor angiogenesis, and highlights its potential as anti-angiogenic therapeutic target in cancer.

Satoh, W., Gotoh, T., Tsunematsu, Y., Aizawa, S., & Shimono, A. (2006). Sfrp1 and Sfrp2 regulate anteroposterior axis elongation and somite segmentation during mouse embryogenesis. Development, 133(6), 989–999. https://doi.org/10.1242/dev.02274.CrossRefPubMed

Banyai, L., & Patthy, L. (1999). The NTR module: domains of netrins, secreted frizzled related proteins, and type I procollagen C-proteinase enhancer protein are homologous with tissue inhibitors of metalloproteases. Protein Science, 8(8), 1636–1642. https://doi.org/10.1110/ps.8.8.1636.CrossRefPubMedPubMedCentral

Finch, P. W., He, X., Kelley, M. J., Uren, A., Schaudies, R. P., Popescu, N. C., Rudikoff, S., Aaronson, S. A., Varmus, H. E., & Rubin, J. S. (1997). Purification and molecular cloning of a secreted, frizzled-related antagonist of Wnt action. Proceedings of the National Academy of Sciences of the United States of America, 94(13), 6770–6775. https://doi.org/10.1073/pnas.94.13.6770.CrossRefPubMedPubMedCentral

Jung, Y. S., & Park, J. I. (2020). Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond β-catenin and the destruction complex. Experimental & Molecular Medicine, 52(2), 183–191. https://doi.org/10.1038/s12276-020-0380-6.CrossRef

Bhati, R., Patterson, C., Livasy, C. A., Fan, C., Ketelsen, D., Hu, Z., Reynolds, E., Tanner, C., Moore, D. T., Gabrielli, F., Perou, C. M., & Klauber-DeMore, N. (2008). Molecular characterization of human breast tumor vascular cells. The American Journal of Pathology, 172(5), 1381–1390. https://doi.org/10.2353/ajpath.2008.070988.CrossRefPubMedPubMedCentral

Tsuruta, J. K., Klauber-DeMore, N., Streeter, J., Samples, J., Patterson, C., Mumper, R. J., Ketelsen, D., & Dayton, P. (2014). Ultrasound molecular imaging of secreted frizzled related protein-2 expression in murine angiosarcoma. PLoS One, 9(1), e86642. https://doi.org/10.1371/journal.pone.0086642.CrossRefPubMedPubMedCentral

Ramjiawan, R. R., Griffioen, A. W., & Duda, D. G. (2017). Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy? Angiogenesis, 20(2), 185–204. https://doi.org/10.1007/s10456-017-9552-y.CrossRefPubMedPubMedCentral

van Loon, K., Yemelyanenko-Lyalenko, J., Margadant, C., Griffioen, A. W., & Huijbers, E. J. M. (2020). Role of fibrillin-2 in the control of TGF-β activation in tumor angiogenesis and connective tissue disorders. Biochimica Et Biophysica Acta. Reviews on Cancer, 1873(2), 188354. https://doi.org/10.1016/j.bbcan.2020.188354.

Huijbers, E. J. M., van der Werf, I. M., Faber, L. D., Sialino, L. D., van der Laan, P., Holland, H. A., Cimpean, A. M., Thijssen, V. L. J. L., van Beijnum, J. R., & Griffioen, A. W. (2019). Targeting tumor vascular CD99 inhibits tumor growth. Frontiers in Immunology, 10, 651. https://doi.org/10.3389/fimmu.2019.00651.CrossRefPubMedPubMedCentral

10.

Zhan, T., Rindtorff, N., & Boutros, M. (2017). Wnt signaling in cancer. Oncogene, 36(11), 1461–1473. https://doi.org/10.1038/onc.2016.304.CrossRefPubMed

11.

Sharma, R. (1973). Wingless, a new mutant in D. melanogaster. Drosophila Information Service, 50, 134.

12.

Nusse, R., & Varmus, H. E. (1982). Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell, 31(1), 99–109. https://doi.org/10.1016/0092-8674(82)90409-3.CrossRefPubMed

13.

Rijsewijk, F., Schuermann, M., Wagenaar, E., Parren, P., Weigel, D., & Nusse, R. (1987). The Drosophila homolog of the mouse mammary oncogene int-1 is identical to the segment polarity gene wingless. Cell, 50(4), 649–657. https://doi.org/10.1016/0092-8674(87)90038-9.CrossRefPubMed

14.

Shirozu, M., Tada, H., Tashiro, K., Nakamura, T., Lopez, N. D., Nazarea, M., Hamada, T., Sato, T., Nakano, T., & Honjo, T. (1996). Characterization of novel secreted and membrane proteins isolated by the signal sequence trap method. Genomics, 37(3), 273–280. https://doi.org/10.1006/geno.1996.0560.CrossRefPubMed

15.

Melkonyan, H. S., Chang, W. C., Shapiro, J. P., Mahadevappa, M., Fitzpatrick, P. A., Kiefer, M. C., Tomei, L. D., & Umansky, S. R. (1997). SARPs: a family of secreted apoptosis-related proteins. Proceedings of the National Academy of Sciences of the United States of America, 94(25), 13636–13641. https://doi.org/10.1073/pnas.94.25.13636.CrossRefPubMedPubMedCentral

16.

Katoh, M., & Katoh, M. (2005). Comparative genomics on SFRP2 orthologs. Oncology Reports, 14(3), 783–787. https://doi.org/10.3892/or.14.3.783.CrossRefPubMed

17.

Benhaj, K., Akcali, K. C., & Ozturk, M. (2006). Redundant expression of canonical Wnt ligands in human breast cancer cell lines. Oncology Reports, 15(3), 701–707. https://doi.org/10.3892/or.15.3.701.CrossRefPubMed

18.

Wu, Y., Liu, X., Zheng, H., Zhu, H., Mai, W., Huang, X., & Huang, Y. (2020). Multiple roles of sFRP2 in cardiac development and cardiovascular disease. International Journal of Biological Sciences, 16(5), 730–738. https://doi.org/10.7150/ijbs.40923.CrossRefPubMedPubMedCentral

19.

Alfaro, M. P., Vincent, A., Saraswati, S., Thorne, C. A., Hong, C. C., Lee, E., & Young, P. P. (2010). sFRP2 suppression of bone morphogenic protein (BMP) and Wnt signaling mediates mesenchymal stem cell (MSC) self-renewal promoting engraftment and myocardial repair. The Journal of Biological Chemistry, 285(46), 35645–35653. https://doi.org/10.1074/jbc.M110.135335.CrossRefPubMedPubMedCentral

20.

Wawrzak, D., Metioui, M., Willems, E., Hendrickx, M., de Genst, E., & Leyns, L. (2007). Wnt3a binds to several sFRPs in the nanomolar range. Biochemical and Biophysical Research Communications, 357(4), 1119–1123. https://doi.org/10.1016/j.bbrc.2007.04.069.CrossRefPubMed

21.

Hua, Y., Yang, Y., Li, Q., He, X., Zhu, W., Wang, J., & Gan, X. (2018). Oligomerization of frizzled and LRP5/6 protein initiates intracellular signaling for the canonical WNT/beta-catenin pathway. The Journal of Biological Chemistry, 293(51), 19710–19724. https://doi.org/10.1074/jbc.RA118.004434.CrossRefPubMedPubMedCentral

22.

Galli, L. M., Barnes, T., Cheng, T., Acosta, L., Anglade, A., Willert, K., Nusse, R., & Burrus, L. W. (2006). Differential inhibition of Wnt-3a by Sfrp-1, Sfrp-2, and Sfrp-3. Developmental Dynamics, 235(3), 681–690. https://doi.org/10.1002/dvdy.20681.CrossRefPubMedPubMedCentral

23.

Morello, R., Bertin, T. K., Schlaubitz, S., Shaw, C. A., Kakuru, S., Munivez, E., Hermanns, P., Chen, Y., Zabel, B., & Lee, B. (2008). Brachy-syndactyly caused by loss of Sfrp2 function. Journal of Cellular Physiology, 217(1), 127–137. https://doi.org/10.1002/jcp.21483.CrossRefPubMedPubMedCentral

24.

Zhang, Z., Deb, A., Zhang, Z., Pachori, A., He, W., Guo, J., Pratt, R., & Dzau, V. J. (2009). Secreted frizzled related protein 2 protects cells from apoptosis by blocking the effect of canonical Wnt3a. Journal of Molecular and Cellular Cardiology, 46(3), 370–377. https://doi.org/10.1016/j.yjmcc.2008.11.016.CrossRefPubMed

25.

Kress, E., Rezza, A., Nadjar, J., Samarut, J., & Plateroti, M. (2009). The frizzled-related sFRP2 gene is a target of thyroid hormone receptor alpha1 and activates beta-catenin signaling in mouse intestine. The Journal of Biological Chemistry, 284(2), 1234–1241. https://doi.org/10.1074/jbc.M806548200.CrossRefPubMed

26.

Mastri, M., Shah, Z., Hsieh, K., Wang, X., Wooldridge, B., Martin, S., Suzuki, G., & Lee, T. (2014). Secreted frizzled-related protein 2 as a target in antifibrotic therapeutic intervention. American Journal of Physiology. Cell Physiology, 306(6), C531–C539. https://doi.org/10.1152/ajpcell.00238.2013.CrossRefPubMed

27.

Lin, M., Liu, X., Zheng, H., Huang, X., Wu, Y., Huang, A., Zhu, H., Hu, Y., Mai, W., & Huang, Y. (2020). IGF-1 enhances BMSC viability, migration, and anti-apoptosis in myocardial infarction via secreted frizzled-related protein 2 pathway. Stem Cell Research & Therapy, 11(1), 22. https://doi.org/10.1186/s13287-019-1544-y.CrossRef

28.

Heinosalo, T., Gabriel, M., Kallio, L., Adhikari, P., Huhtinen, K., Laajala, T. D., Kaikkonen, E., Mehmood, A., Suvitie, P., Kujari, H., Aittokallio, T., Perheentupa, A., & Poutanen, M. (2018). Secreted frizzled-related protein 2 (SFRP2) expression promotes lesion proliferation via canonical WNT signaling and indicates lesion borders in extraovarian endometriosis. Human Reproduction, 33(5), 817–831. https://doi.org/10.1093/humrep/dey026.CrossRefPubMed

29.

von Marschall, Z., & Fisher, L. W. (2010). Secreted frizzled-related protein-2 (sFRP2) augments canonical Wnt3a-induced signaling. Biochemical and Biophysical Research Communications, 400(3), 299–304. https://doi.org/10.1016/j.bbrc.2010.08.043.CrossRef

30.

Skah, S., Nadjar, J., Sirakov, M., & Plateroti, M. (2015). The secreted frizzled-related protein 2 modulates cell fate and the Wnt pathway in the murine intestinal epithelium. Experimental Cell Research, 330(1), 56–65. https://doi.org/10.1016/j.yexcr.2014.10.014.CrossRefPubMed

31.

Xavier, C. P., Melikova, M., Chuman, Y., Uren, A., Baljinnyam, B., & Rubin, J. S. (2014). Secreted frizzled-related protein potentiation versus inhibition of Wnt3a/beta-catenin signaling. Cellular Signalling, 26(1), 94–101. https://doi.org/10.1016/j.cellsig.2013.09.016.CrossRefPubMed

32.

Brinkmann, E. M., Mattes, B., Kumar, R., Hagemann, A. I., Gradl, D., Scholpp, S., et al. (2016). Secreted frizzled-related protein 2 (sFRP2) redirects non-canonical Wnt signaling from Fz7 to Ror2 during vertebrate gastrulation. The Journal of Biological Chemistry, 291(26), 13730–13742. https://doi.org/10.1074/jbc.M116.733766.CrossRefPubMedPubMedCentral

33.

Kele, J., Andersson, E. R., Villaescusa, J. C., Cajanek, L., Parish, C. L., Bonilla, S., Toledo, E. M., Bryja, V., Rubin, J. S., Shimono, A., & Arenas, E. (2012). SFRP1 and SFRP2 dose-dependently regulate midbrain dopamine neuron development in vivo and in embryonic stem cells. Stem Cells, 30(5), 865–875. https://doi.org/10.1002/stem.1049.CrossRefPubMedPubMedCentral

34.

Qin, J. J., Nag, S., Wang, W., Zhou, J., Zhang, W. D., Wang, H., & Zhang, R. (2014). NFAT as cancer target: mission possible? Biochimica et Biophysica Acta, 1846(2), 297–311. https://doi.org/10.1016/j.bbcan.2014.07.009.CrossRefPubMedPubMedCentral

35.

Peterson, Y. K., Nasarre, P., Bonilla, I. V., Hilliard, E., Samples, J., Morinelli, T. A., Hill, E. G., & Klauber-DeMore, N. (2017). Frizzled-5: a high affinity receptor for secreted frizzled-related protein-2 activation of nuclear factor of activated T-cells c3 signaling to promote angiogenesis. Angiogenesis, 20(4), 615–628. https://doi.org/10.1007/s10456-017-9574-5.CrossRefPubMedPubMedCentral

36.

Ikegawa, M., Han, H., Okamoto, A., Matsui, R., Tanaka, M., Omi, N., Miyamae, M., Toguchida, J., & Tashiro, K. (2008). Syndactyly and preaxial synpolydactyly in the single Sfrp2 deleted mutant mice. Developmental Dynamics, 237(9), 2506–2517. https://doi.org/10.1002/dvdy.21655.CrossRefPubMed

37.

Misra, K., & Matise, M. P. (2010). A critical role for sFRP proteins in maintaining caudal neural tube closure in mice via inhibition of BMP signaling. Developmental Biology, 337(1), 74–83. https://doi.org/10.1016/j.ydbio.2009.10.015.CrossRefPubMed

38.

Warr, N., Siggers, P., Bogani, D., Brixey, R., Pastorelli, L., Yates, L., Dean, C. H., Wells, S., Satoh, W., Shimono, A., & Greenfield, A. (2009). Sfrp1 and Sfrp2 are required for normal male sexual development in mice. Developmental Biology, 326(2), 273–284. https://doi.org/10.1016/j.ydbio.2008.11.023.CrossRefPubMed

39.

Giles, R. H., van Es, J. H., & Clevers, H. (2003). Caught up in a Wnt storm: Wnt signaling in cancer. Biochimica et Biophysica Acta, 1653(1), 1–24. https://doi.org/10.1016/s0304-419x(03)00005-2.CrossRefPubMed

40.

Howe, L. R., & Brown, A. M. (2004). Wnt signaling and breast cancer. Cancer Biology & Therapy, 3(1), 36–41. https://doi.org/10.4161/cbt.3.1.561.CrossRef

41.

Mazieres, J., He, B., You, L., Xu, Z., & Jablons, D. M. (2005). Wnt signaling in lung cancer. Cancer Letters, 222(1), 1–10. https://doi.org/10.1016/j.canlet.2004.08.040.CrossRefPubMed

42.

Chung, M. T., Lai, H. C., Sytwu, H. K., Yan, M. D., Shih, Y. L., Chang, C. C., Yu, M. H., Liu, H. S., Chu, D. W., & Lin, Y. W. (2009). SFRP1 and SFRP2 suppress the transformation and invasion abilities of cervical cancer cells through Wnt signal pathway. Gynecologic Oncology, 112(3), 646–653. https://doi.org/10.1016/j.ygyno.2008.10.026.CrossRefPubMed

43.

Xiao, C., Wang, L., Zhu, L., Zhang, C., & Zhou, J. (2014). Secreted frizzledrelated protein 2 is epigenetically silenced and functions as a tumor suppressor in oral squamous cell carcinoma. Molecular Medicine Reports, 10(5), 2293–2298. https://doi.org/10.3892/mmr.2014.2542.CrossRefPubMedPubMedCentral

44.

Kaur, A., Webster, M. R., Marchbank, K., Behera, R., Ndoye, A., Kugel 3rd, C. H., et al. (2016). sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature, 532(7598), 250–254. https://doi.org/10.1038/nature17392.CrossRefPubMedPubMedCentral

45.

Marsit, C. J., Karagas, M. R., Andrew, A., Liu, M., Danaee, H., Schned, A. R., Nelson, H. H., & Kelsey, K. T. (2005). Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer. Cancer Research, 65(16), 7081–7085. https://doi.org/10.1158/0008-5472.can-05-0267.CrossRefPubMed

46.

Li, Z., Guo, X., Wu, Y., Li, S., Yan, J., Peng, L., Xiao, Z., Wang, S., Deng, Z., Dai, L., Yi, W., Xia, K., Tang, L., & Wang, J. (2015). Methylation profiling of 48 candidate genes in tumor and matched normal tissues from breast cancer patients. Breast Cancer Research and Treatment, 149(3), 767–779. https://doi.org/10.1007/s10549-015-3276-8.CrossRefPubMed

47.

Lin, Y. W., Chung, M. T., Lai, H. C., De Yan, M., Shih, Y. L., Chang, C. C., et al. (2009). Methylation analysis of SFRP genes family in cervical adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 135(12), 1665–1674. https://doi.org/10.1007/s00432-009-0613-5.CrossRefPubMed

48.

Liu, X., Fu, J., Bi, H., Ge, A., Xia, T., Liu, Y., Sun, H., Li, D., & Zhao, Y. (2019). DNA methylation of SFRP1, SFRP2, and WIF1 and prognosis of postoperative colorectal cancer patients. BMC Cancer, 19(1), 1212. https://doi.org/10.1186/s12885-019-6436-0.CrossRefPubMedPubMedCentral

49.

Zou, H., Molina, J. R., Harrington, J. J., Osborn, N. K., Klatt, K. K., Romero, Y., Burgart, L. J., & Ahlquist, D. A. (2005). Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett’s esophagus. International Journal of Cancer, 116(4), 584–591. https://doi.org/10.1002/ijc.21045.CrossRefPubMed

50.

Zhang, Y., Yang, B., Du, Z., Gao, Y. T., Wang, Y. J., Jing, X., et al. (2010). Identification and validation of specific methylation profile in bile for differential diagnosis of malignant biliary stricture. Clinical Biochemistry, 43(16–17), 1340–1344. https://doi.org/10.1016/j.clinbiochem.2010.08.013.CrossRefPubMed

51.

Cheng, Y. Y., Yu, J., Wong, Y. P., Man, E. P., To, K. F, Jin, V. X., et al. (2007). Frequent epigenetic inactivation of secreted frizzled-related protein 2 (SFRP2) by promoter methylation in human gastric cancer. British Journal of Cancer, 97(7), 895–901. https://doi.org/10.1038/sj.bjc.6603968.CrossRefPubMedPubMedCentral

52.

Takagi, H., Sasaki, S., Suzuki, H., Toyota, M., Maruyama, R., Nojima, M., Yamamoto, H., Omata, M., Tokino, T., Imai, K., & Shinomura, Y. (2008). Frequent epigenetic inactivation of SFRP genes in hepatocellular carcinoma. Journal of Gastroenterology, 43(5), 378–389. https://doi.org/10.1007/s00535-008-2170-0.CrossRefPubMed

53.

Liu, S., Chen, X., Chen, R., Wang, J., Zhu, G., Jiang, J., et al. (2017). Diagnostic role of Wnt pathway gene promoter methylation in non small cell lung cancer. Oncotarget, 8(22), 36354–36367. https://doi.org/10.18632/oncotarget.16754.CrossRefPubMedPubMedCentral

54.

Su, H. Y., Lai, H. C., Lin, Y. W., Chou, Y. C., Liu, C. Y., & Yu, M. H. (2009). An epigenetic marker panel for screening and prognostic prediction of ovarian cancer. International Journal of Cancer, 124(2), 387–393. https://doi.org/10.1002/ijc.23957.CrossRefPubMed

55.

Bu, X. M., Zhao, C. H., Zhang, N., Gao, F., Lin, S., & Dai, X. W. (2008). Hypermethylation and aberrant expression of secreted frizzled-related protein genes in pancreatic cancer. World Journal of Gastroenterology, 14(21), 3421–3424. https://doi.org/10.3748/wjg.14.3421.CrossRefPubMedPubMedCentral

56.

Perry, A. S., O’Hurley, G., Raheem, O. A., Brennan, K., Wong, S., O’Grady, A., Kennedy, A. M., Marignol, L., Murphy, T. M., Sullivan, L., Barrett, C., Loftus, B., Thornhill, J., Hewitt, S. M., Lawler, M., Kay, E., Lynch, T., & Hollywood, D. (2013). Gene expression and epigenetic discovery screen reveal methylation of SFRP2 in prostate cancer. International Journal of Cancer, 132(8), 1771–1780. https://doi.org/10.1002/ijc.27798.CrossRefPubMed

57.

Suehiro, Y., Okada, T., Okada, T., Anno, K., Okayama, N., Ueno, K., Hiura, M., Nakamura, M., Kondo, T., Oga, A., Kawauchi, S., Hirabayashi, K., Numa, F., Ito, T., Saito, T., Sasaki, K., & Hinoda, Y. (2008). Aneuploidy predicts outcome in patients with endometrial carcinoma and is related to lack of CDH13 hypermethylation. Clinical Cancer Research, 14(11), 3354–3361. https://doi.org/10.1158/1078-0432.ccr-07-4609.CrossRefPubMed

58.

Xiao, Q., Yang, Y., Zhang, X., & An, Q. (2016). Enhanced Wnt signaling by methylation-mediated loss of SFRP2 promotes osteosarcoma cell invasion. Tumour Biology, 37(5), 6315–6321. https://doi.org/10.1007/s13277-015-4466-z.CrossRefPubMed

59.

Liang, J., Kang, X., Halifu, Y., Zeng, X., Jin, T., Zhang, M., Luo, D., Ding, Y., Zhou, Y., Yakeya, B., Abudu, D., & Pu, X. (2015). Secreted frizzled-related protein promotors are hypermethylated in cutaneous squamous carcinoma compared with normal epidermis. BMC Cancer, 15, 641. https://doi.org/10.1186/s12885-015-1650-x.CrossRefPubMedPubMedCentral

60.

Gotze, S., Wolter, M., Reifenberger, G., Muller, O., & Sievers, S. (2010). Frequent promoter hypermethylation of Wnt pathway inhibitor genes in malignant astrocytic gliomas. International Journal of Cancer, 126(11), 2584–2593. https://doi.org/10.1002/ijc.24981.CrossRefPubMed

61.

Ren, J., Jian, F., Jiang, H., Sun, Y., Pan, S., Gu, C., Chen, X., Wang, W., Ning, G., Bian, L., & Sun, Q. (2018). Decreased expression of SFRP2 promotes development of the pituitary corticotroph adenoma by upregulating Wnt signaling. International Journal of Oncology, 52(6), 1934–1946. https://doi.org/10.3892/ijo.2018.4355.CrossRefPubMedPubMedCentral

62.

Zeng, X., Zhang, Y., Xu, H., Zhang, T., Xue, Y., & An, R. (2018). Secreted frizzled related protein 2 modulates epithelial-mesenchymal transition and Stemness via Wnt/beta-catenin signaling in choriocarcinoma. Cellular Physiology and Biochemistry, 50(5), 1815–1831. https://doi.org/10.1159/000494862.CrossRefPubMed

63.

Li, P., Zhao, S., & Hu, Y. (2019). SFRP2 modulates nonsmall cell lung cancer A549 cell apoptosis and metastasis by regulating mitochondrial fission via Wnt pathways. Molecular Medicine Reports, 20(2), 1925–1932. https://doi.org/10.3892/mmr.2019.10393.CrossRefPubMed

64.

Han, M., Wang, S., Fritah, S., Wang, X., Zhou, W., Yang, N., Ni, S., Huang, B., Chen, A., Li, G., Miletic, H., Thorsen, F., Bjerkvig, R., Li, X., & Wang, J. (2020). Interfering with long non-coding RNA MIR22HG processing inhibits glioblastoma progression through suppression of Wnt/beta-catenin signalling. Brain, 143(2), 512–530. https://doi.org/10.1093/brain/awz406.CrossRefPubMed

65.

Leventoux, N., Augustus, M., Azar, S., Riquier, S., Villemin, J. P., Guelfi, S., Falha, L., Bauchet, L., Gozé, C., Ritchie, W., Commes, T., Duffau, H., Rigau, V., & Hugnot, J. P. (2020). Transformation foci in IDH1-mutated gliomas show STAT3 phosphorylation and downregulate the metabolic enzyme ETNPPL, a negative regulator of glioma growth. Scientific Reports, 10(1), 5504. https://doi.org/10.1038/s41598-020-62145-1.CrossRefPubMedPubMedCentral

66.

Wu, Y., Bai, J., Hong, L., Liu, C., Yu, S., Yu, G., et al. (2016). Low expression of secreted frizzled-related protein 2 and nuclear accumulation of beta-catenin in aggressive nonfunctioning pituitary adenoma. Oncology Letters, 12(1), 199–206. https://doi.org/10.3892/ol.2016.4560.CrossRefPubMedPubMedCentral

67.

Esteve, P., & Bovolenta, P. (2010). The advantages and disadvantages of sfrp1 and sfrp2 expression in pathological events. The Tohoku Journal of Experimental Medicine, 221(1), 11–17. https://doi.org/10.1620/tjem.221.11.CrossRefPubMed

68.

Lee, J. L., Chang, C. J., Chueh, L. L., & Lin, C. T. (2003). Expression of secreted frizzled-related protein 2 in a primary canine mammary tumor cell line: A candidate tumor marker for mammary tumor cells. In Vitro Cellular & Developmental Biology. Animal, 39(5–6), 221–227. https://doi.org/10.1290/1543-706x(2003)039<0221:eosfpi>2.0.co;2.CrossRef

69.

Techavichit, P., Gao, Y., Kurenbekova, L., Shuck, R., Donehower, L. A., & Yustein, J. T. (2016). Secreted frizzled-related protein 2 (sFRP2) promotes osteosarcoma invasion and metastatic potential. BMC Cancer, 16(1), 869. https://doi.org/10.1186/s12885-016-2909-6.CrossRefPubMedPubMedCentral

70.

Oshima, T., Abe, M., Asano, J., Hara, T., Kitazoe, K., Sekimoto, E., Tanaka, Y., Shibata, H., Hashimoto, T., Ozaki, S., Kido, S., Inoue, D., & Matsumoto, T. (2005). Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood, 106(9), 3160–3165. https://doi.org/10.1182/blood-2004-12-4940.CrossRefPubMed

71.

Huang, C., Ye, Z., Wan, J., Liang, J., Liu, M., Xu, X., & Li, L. (2019). Secreted frizzled-related protein 2 is associated with disease progression and poor prognosis in breast cancer. Disease Markers, 2019, 6149381–6149387. https://doi.org/10.1155/2019/6149381.CrossRefPubMedPubMedCentral

72.

Hill, V. K., Ricketts, C., Bieche, I., Vacher, S., Gentle, D., Lewis, C., Maher, E. R., & Latif, F. (2011). Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity. Cancer Research, 71(8), 2988–2999. https://doi.org/10.1158/0008-5472.can-10-4026.CrossRefPubMed

73.

Mohammed, S. I., Utturkar, S., Lee, M., Yang, H. H., Cui, Z., Atallah Lanman, N., et al. (2020). Ductal carcinoma in situ progression in dog model of breast cancer. Cancers (Basel), 12(2). https://doi.org/10.3390/cancers12020418.

74.

Kim, H., Yoo, S., Zhou, R., Xu, A., Bernitz, J. M., Yuan, Y., Gomes, A. M., Daniel, M. G., Su, J., Demicco, E. G., Zhu, J., Moore, K. A., Lee, D. F., Lemischka, I. R., & Schaniel, C. (2018). Oncogenic role of SFRP2 in p53-mutant osteosarcoma development via autocrine and paracrine mechanism. Proceedings of the National Academy of Sciences of the United States of America, 115(47), E11128–e11137. https://doi.org/10.1073/pnas.1814044115.CrossRefPubMedPubMedCentral

75.

Vincent, K. M., & Postovit, L. M. (2017). A pan-cancer analysis of secreted frizzled-related proteins: re-examining their proposed tumour suppressive function. Scientific Reports, 7, 42719. https://doi.org/10.1038/srep42719.CrossRefPubMedPubMedCentral

76.

Yamamura, S., Kawakami, K., Hirata, H., Ueno, K., Saini, S., Majid, S., & Dahiya, R. (2010). Oncogenic functions of secreted frizzled-related protein 2 in human renal cancer. Molecular Cancer Therapeutics, 9(6), 1680–1687. https://doi.org/10.1158/1535-7163.mct-10-0012.CrossRefPubMed

77.

Roth, W., Wild-Bode, C., Platten, M., Grimmel, C., Melkonyan, H. S., Dichgans, J., & Weller, M. (2000). Secreted frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells. Oncogene, 19(37), 4210–4220. https://doi.org/10.1038/sj.onc.1203783.CrossRefPubMed

78.

Fontenot, E., Rossi, E., Mumper, R., Snyder, S., Siamakpour-Reihani, S., Ma, P., Hilliard, E., Bone, B., Ketelsen, D., Santos, C., Patterson, C., & Klauber-DeMore, N. (2013). A novel monoclonal antibody to secreted frizzled-related protein 2 inhibits tumor growth. Molecular Cancer Therapeutics, 12(5), 685–695. https://doi.org/10.1158/1535-7163.mct-12-1066.CrossRefPubMedPubMedCentral

79.

Garcia, D., Nasarre, P., Bonilla, I. V., Hilliard, E., Peterson, Y. K., Spruill, L., Broome, A. M., Hill, E. G., Yustein, J. T., Mehrotra, S., & Klauber-DeMore, N. (2019). Development of a novel humanized monoclonal antibody to secreted frizzled-related protein-2 that inhibits triple-negative breast cancer and angiosarcoma growth in vivo. Annals of Surgical Oncology, 26(13), 4782–4790. https://doi.org/10.1245/s10434-019-07800-2.CrossRefPubMedPubMedCentral

80.

Xiao, X., Xiao, Y., Wen, R., Zhang, Y., Li, X., Wang, H., et al. (2015). Promoting roles of the secreted frizzled-related protein 2 as a Wnt agonist in lung cancer cells. Oncology Reports, 34(5), 2259–2266. https://doi.org/10.3892/or.2015.4221.CrossRefPubMedPubMedCentral

81.

Wang, Y. (2009). Wnt/planar cell polarity signaling: a new paradigm for cancer therapy. Molecular Cancer Therapeutics, 8(8), 2103–2109. https://doi.org/10.1158/1535-7163.mct-09-0282.CrossRefPubMed

82.

Webster, M. R., Kugel 3rd, C. H., & Weeraratna, A. T. (2015). The Wnts of change: How Wnts regulate phenotype switching in melanoma. Biochimica et Biophysica Acta, 1856(2), 244–251. https://doi.org/10.1016/j.bbcan.2015.10.002.CrossRefPubMedPubMedCentral

83.

Montagner, M., Bhome, R., Hooper, S., Chakravarty, P., Qin, X., Sufi, J., Bhargava, A., Ratcliffe, C. D. H., Naito, Y., Pocaterra, A., Tape, C. J., & Sahai, E. (2020). Crosstalk with lung epithelial cells regulates Sfrp2-mediated latency in breast cancer dissemination. Nature Cell Biology, 22(3), 289–296. https://doi.org/10.1038/s41556-020-0474-3.CrossRefPubMedPubMedCentral

84.

Griffioen, A. W., & Molema, G. (2000). Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacological Reviews, 52(2), 237–268.PubMed

85.

Bielenberg, D. R., & Zetter, B. R. (2015). The contribution of angiogenesis to the process of metastasis. Cancer Journal (Sudbury, Mass.), 21(4), 267–273. https://doi.org/10.1097/PPO.0000000000000138.CrossRef

86.

Kerbel, R., & Folkman, J. (2002). Clinical translation of angiogenesis inhibitors. Nature Reviews Cancer, 2(10), 727–739. https://doi.org/10.1038/nrc905.CrossRefPubMed

87.

Hillen, F., & Griffioen, A. W. (2007). Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Reviews, 26(3–4), 489–502. https://doi.org/10.1007/s10555-007-9094-7.CrossRefPubMedPubMedCentral

88.

Olsen, J. J., Pohl, S. O., Deshmukh, A., Visweswaran, M., Ward, N. C., Arfuso, F., et al. (2017). The role of Wnt Signalling in angiogenesis. Clinical Biochemist Reviews, 38(3), 131–142.PubMedPubMedCentral

89.

Brandt, M. M., van Dijk, C. G. M., Chrifi, I., Kool, H. M., Bürgisser, P. E., Louzao-Martinez, L., Pei, J., Rottier, R. J., Verhaar, M. C., Duncker, D. J., & Cheng, C. (2018). Endothelial loss of Fzd5 stimulates PKC/Ets1-mediated transcription of Angpt2 and Flt1. Angiogenesis, 21(4), 805–821. https://doi.org/10.1007/s10456-018-9625-6.CrossRefPubMedPubMedCentral

90.

Danieau, G., Morice, S., Redini, F., Verrecchia, F., & Royer, B. B. (2019). New insights about the Wnt/beta-catenin signaling pathway in primary bone tumors and their microenvironment: a promising target to develop therapeutic strategies? International Journal of Molecular Sciences, 20(15). https://doi.org/10.3390/ijms20153751.

91.

Easwaran, V., Lee, S. H., Inge, L., Guo, L., Goldbeck, C., Garrett, E., et al. (2003). Beta-catenin regulates vascular endothelial growth factor expression in colon cancer. Cancer Research, 63(12), 3145–3153.PubMed

92.

Rapp, J., Jaromi, L., Kvell, K., Miskei, G., & Pongracz, J. E. (2017). WNT signaling - lung cancer is no exception. Respiratory Research, 18(1), 167. https://doi.org/10.1186/s12931-017-0650-6.CrossRefPubMedPubMedCentral

93.

Cirone, P., Lin, S., Griesbach, H. L., Zhang, Y., Slusarski, D. C., & Crews, C. M. (2008). A role for planar cell polarity signaling in angiogenesis. Angiogenesis, 11(4), 347–360. https://doi.org/10.1007/s10456-008-9116-2.CrossRefPubMedPubMedCentral

94.

van Beijnum, J. R., Dings, R. P., van der Linden, E., Zwaans, B. M., Ramaekers, F. C., Mayo, K. H., et al. (2006). Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood, 108(7), 2339–2348. https://doi.org/10.1182/blood-2006-02-004291.CrossRefPubMed

95.

St Croix, B., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., et al. (2000). Genes expressed in human tumor endothelium. Science, 289(5482), 1197–1202. https://doi.org/10.1126/science.289.5482.1197.CrossRefPubMed

96.

van Beijnum, J. R., & Griffioen, A. W. (2005). In silico analysis of angiogenesis associated gene expression identifies angiogenic stage related profiles. Biochimica et Biophysica Acta, 1755(2), 121–134. https://doi.org/10.1016/j.bbcan.2005.06.001.CrossRefPubMed

97.

Thijssen, V. L., Postel, R., Brandwijk, R. J., Dings, R. P., Nesmelova, I., Satijn, S., et al. (2006). Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proceedings of the National Academy of Sciences of the United States of America, 103(43), 15975–15980. https://doi.org/10.1073/pnas.0603883103.CrossRefPubMedPubMedCentral

98.

Courtwright, A., Siamakpour-Reihani, S., Arbiser, J. L., Banet, N., Hilliard, E., Fried, L., Livasy, C., Ketelsen, D., Nepal, D. B., Perou, C. M., Patterson, C., & Klauber-DeMore, N. (2009). Secreted frizzle-related protein 2 stimulates angiogenesis via a calcineurin/NFAT signaling pathway. Cancer Research, 69(11), 4621–4628. https://doi.org/10.1158/0008-5472.can-08-3402.CrossRefPubMedPubMedCentral

99.

Nowak-Sliwinska, P., Segura, T., & Iruela-Arispe, M. L. (2014). The chicken chorioallantoic membrane model in biology, medicine and bioengineering. Angiogenesis, 17(4), 779–804. https://doi.org/10.1007/s10456-014-9440-7.CrossRefPubMedPubMedCentral

100.

Siamakpour-Reihani, S., Caster, J., Bandhu Nepal, D., Courtwright, A., Hilliard, E., Usary, J., Ketelsen, D., Darr, D., Shen, X. J., Patterson, C., & Klauber-DeMore, N. (2011). The role of calcineurin/NFAT in SFRP2 induced angiogenesis--a rationale for breast cancer treatment with the calcineurin inhibitor tacrolimus. PLoS One, 6(6), e20412. https://doi.org/10.1371/journal.pone.0020412.CrossRefPubMedPubMedCentral

101.

Huijbers, E. J., Ringvall, M., Femel, J., Kalamajski, S., Lukinius, A., Abrink, M., et al. (2010). Vaccination against the extra domain-B of fibronectin as a novel tumor therapy. The FASEB Journal, 24(11), 4535–4544. https://doi.org/10.1096/fj.10-163022.CrossRefPubMed

102.

Huijbers, E. J. M., van Beijnum, J. R., Lê, C. T., Langman, S., Nowak-Sliwinska, P., Mayo, K. H., & Griffioen, A. W. (2018). An improved conjugate vaccine technology; induction of antibody responses to the tumor vasculature. Vaccine, 36(21), 3054–3060. https://doi.org/10.1016/j.vaccine.2018.03.064.CrossRefPubMed

Title: Secreted frizzled-related protein 2: a key player in noncanonical Wnt signaling and tumor angiogenesis
Authors: Karlijn van Loon
Elisabeth J. M. Huijbers
Arjan W. Griffioen
Publication date: 01-03-2021
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 1/2021
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-020-09941-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

An overview of genetic mutations and epigenetic signatures in the course of pancreatic cancer progression

Interaction between adipose tissue and cancer cells: role for cancer progression

Galectin-3: an immune checkpoint target for musculoskeletal tumor patients

Beyond tradition and convention: benefits of non-traditional model organisms in cancer research

Neuroblastoma and the epigenome

Neutrophil-derived granule cargoes: paving the way for tumor growth and progression

Keynote webinar | Spotlight on antibody–drug conjugates in cancer